Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn’s Disease

BACKGROUND: This randomized, open-label phase 2a study investigated the safety/tolerability, pharmacokinetics, and efficacy of olorinab—a highly selective, peripherally acting, full agonist of the cannabinoid receptor 2—in patients with Crohn’s disease (CD) experiencing abdominal pain. METHODS: Elig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yacyshyn, Bruce R, Hanauer, Stephen, Klassen, Preston, English, Brett A, Stauber, Kathe, Barish, Charles F, Gilder, Kye, Turner, Stewart, Higgins, Peter D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802051/
https://www.ncbi.nlm.nih.gov/pubmed/36777064
http://dx.doi.org/10.1093/crocol/otaa089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802051/
https://www.ncbi.nlm.nih.gov/pubmed/36777064
http://dx.doi.org/10.1093/crocol/otaa089

Ejemplares similares